# Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

> **NCT02908516** · PHASE4 · TERMINATED · sponsor: **Yale University** · enrollment: 6 (actual)

## Conditions studied

- Hip Fractures
- Blood Loss

## Interventions

- **DRUG:** Tranexamic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02908516
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-18
- **Primary completion:** 2017-11-14
- **Final completion:** 2017-12-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study was terminated due to inability to recruit and collect follow up outcome data.
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908516, "Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02908516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*